ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2427

Enhanced Expression Of mRNA For Triggering Receptor Expressed On Myeloid Cells 1 In CD34+ Cells Of The Bone Marrow In Rheumatoid Arthritis

Tatsuo Nagai1, Tetsuya Tomita2, Hideki Yoshikawa2 and Shunsei Hirohata3, 1Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, 2Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, 3Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Bone marrow, polymerase chain reaction (PCR) and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis: Human Etiology and Pathogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: We previously showed that bone marrow (BM) CD34+ cells from rheumatoid arthritis (RA) patients have abnormal capacities to respond to tumor necrosis factor alpha and to differentiate into fibroblast-like cells producing MMP-1, resembling type B synoviocyte. In addition, we have recently demonstrated that the mRNA expression of nuclear factor kappa B1 (NFkB1) (p50), Krüppel-like factor 5 (KLF-5) and FK506-binding protein 5 (FKBP5) in BM CD34+ cells is significantly higher in RA patients than osteoarthritis (OA) patients. Triggering receptor expressed on myeloid cells 1 (TREM-1) is a recently identified cell surface receptor that is inducible mainly on monocytes and neutrophils, and plays an important role as amplifier of inflammatory response in acute and chronic inflammatory conditions. Recent studies have disclosed increased TREM-1 expression in rheumatoid synovial tissue, and have suggested that TREM-1 ligation contributes to the pathogenesis of RA. The current study therefore examined the mRNA expression of TREM-1 in BM CD34+ cells from RA patients.

Methods: BM samples were obtained from 48 patients with RA (6 males and 42 females: mean age 58.8 years) and 30 patients with OA (3 males and 27 females: mean age 71.1 years), who gave informed consent, during joint operations via aspiration from iliac crest. CD34+ cells were purified from the BM mononuclear cells by positive selection with magnetic beads. The expression of mRNA for TREM-1 was examined by quantitative reverse transcription PCR and is shown as the ratio of the copy numbers to those of beta-actin mRNA.

Results: The expression of mRNA for TREM-1 was significantly higher in RA BM CD34+ cells than OA BM CD34+ cells (Fig. A). The TREM-1 mRNA expression level was not correlated with serum C-reactive protein or with the administration of methotrexate or oral steroid (Fig. B). TREM-1 mRNA expression was significantly correlated with NFkB1 (r=0.56, p<0.0001), KLF-5 (r=0.75, p<0.0001) and FKBP5 (r=0.62, p<0.0001) mRNA expression in RA BM CD34+ cells.

Conclusion: These results indicate that the enhanced expression of TREM-1 mRNA in BM CD34+ cells plays a pivotal role in the pathogenesis of RA, and might be secondary to the enhanced mRNA expression of NFkB1, KLF-5 or FKBP5.


Disclosure:

T. Nagai,
None;

T. Tomita,
None;

H. Yoshikawa,
None;

S. Hirohata,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/enhanced-expression-of-mrna-for-triggering-receptor-expressed-on-myeloid-cells-1-in-cd34-cells-of-the-bone-marrow-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology